RESUMEN
Objective: The aim of this study was to evaluate the effect of rosiglitazone on spontaneous and clomiphene-induced cycle in polycystic ovary syndrome (PCOS) women. Methods: A randomized controlled trial was carried out on 30 women of PCOS divided into two groups of 15 each. Group I women received rosiglitazone and Group II women received both rosiglitazone and clomiphene citrate for three months. Main outcome measures: Primary outcome measures were improvement in body mass index (BMI), Hirsutism scoring and ovulation rate. Secondary outcome measures included conception rate and changes in hormonal profile. Results: Overall 20 of 30 (66.67%) women ovulated successfully. Ovulation occurred in nine of 15 women (60.00%) in Group I as compared to 11 of 15 (73.33%) in Group II (p value 0.6). Out of 30, total 53.33% became pregnant, 40% from Group I and 66.67% from Group II (p value 0.14). No significant improvement in follicle-stimulating hormone (FSH) and Hirsutism score was observed. Mean BMI of patient improved significantly and fasting insulin declined but not statistically significant. The hormonal profile showed improvement in both the groups, with decline in luteinizing hormone (LH), LH/FSH ratio and testosterone. Conclusion: Thus rosiglitazone, a wonderful insulin sensitizer, plays a significant role alone as well as in adjunct with clomiphene citrate in PCOS women.